CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

CAR-T cell therapy achieves 18-year survival milestone in cancer patient Innovative cancer treatment shows promise as ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...